CJR-X final rule represents a new era of value-based care at a national scale, holding all acute-care hospitals accountable for care related to joint replacements, with bold moves away from fee-for-service.SAN FRANCISCO, July 31, 2026 /PRNewswire/ -- Today,…
HANGZHOU, China, July 31, 2026 /PRNewswire/ -- CellOrigin, a biotechnology company focused on next-generation in vivo and in vitro cell therapy technologies, has announced two major progresses in both research and strategic partnership. At the 2026 ASCO Annual Meeting,…
Research presented by Taipei American School student Jeffrey Zi Kang Huang at ESHRE 2026 through an international collaboration among Taiwan IVF Group, Ton Yen General Hospital, and Stanford University.LONDON, July 29, 2026 /PRNewswire/ -- An international study examining…
Native ambient scribe based on actual documentation of clinicians across physical therapy, occupational therapy, and speech-language pathology; reduces documentation time by up to 20 minutesPITTSBURGH, July 28, 2026 /PRNewswire/ -- Net Health, an AI-native specialty platform serving clinicians…
Behavioral health leader brings more than 12 years of experience developing client-centered treatment programs for substance use, eating disorders and complex mental health conditionsBOISE, Idaho, July 28, 2026 /PRNewswire/ -- Icarus Wellness and Recovery announced Mallory Harris, MBA,…
MEQUON, Wis. and LENEXA, Kan., July 28, 2026 /PRNewswire/ -- LyoGenesis Plus 1, LLC ("LyoGenesis Plus"), a company related to Vector Science & Therapeutics Corp. ("Vector"), and Wynn Pharmaceuticals LLC ("Wynn") today announced they have entered into a…
MANASSAS, Va., July 25, 2026 /PRNewswire/ -- Proactive wellness has become one of the most talked-about themes in health circles – and daily nutritional support is a big part of why. PureHealth Research optimal health supplements, built around a blend…
PALMA DE MALLORCA, Spain, July 23, 2026 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, today announced that the last patient has completed their last visit (LPLV)…
The U.S. FDA has granted Fast Track designation to Lu AH69593, an oral orexin 2 receptor agonist, for the treatment of patients with narcolepsyThe orexin 2 receptor is critically located in the main biological pathway involved in wakefulness…
TOKYO, July 23, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today an investment of JPY 140 million (approximately USD 862,000) in a project to develop a portable rapid diagnostic system for Ebola disease. The…